In an adult with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia who is on maximally tolerated statin therapy but has not achieved LDL‑cholesterol target, how long should treatment with a PCSK9 inhibitor (alirocumab or evolocumab) be continued?

Duration of PCSK9 Inhibitor Therapy

PCSK9 inhibitors should be continued indefinitely as long-term therapy in patients with ASCVD or heterozygous familial hypercholesterolemia who remain above LDL-C targets despite maximally tolerated statin plus ezetimibe, with ongoing monitoring every 4-12 weeks initially and annually thereafter. 1

Evidence Base for Long-Term Treatment

The current evidence supports continuous, indefinite therapy rather than time-limited treatment:

• Clinical trial data extend to approximately 3 years of treatment (median 2.2-2.8 years in FOURIER and ODYSSEY OUTCOMES), demonstrating sustained cardiovascular benefit with 15% relative risk reduction in major adverse cardiovascular events. 1

• Long-term safety data are available for up to 4 years of continuous PCSK9 inhibitor exposure, showing no cumulative adverse effects, no increase in muscle symptoms, liver enzyme elevation, cognitive impairment, or hemorrhagic stroke. 1

• Guidelines acknowledge uncertainty beyond 3 years but do not recommend discontinuation at any specific timepoint. The 2018 ACC/AHA guideline explicitly states that "long-term safety (>3 years) is uncertain" but this is framed as a knowledge gap rather than a reason to stop therapy. 1

Rationale for Indefinite Continuation

The pathophysiology of ASCVD and familial hypercholesterolemia requires ongoing LDL-C reduction:

• Lifetime LDL-C exposure drives atherosclerotic risk. Mendelian randomization studies demonstrate that earlier and longer duration of LDL-C lowering produces greater cardiovascular benefit, with the number needed to treat in adolescent FH patients being only 2 to prevent one myocardial infarction. 2

• Statin legacy benefit data suggest continued treatment is superior. The West of Scotland Coronary Prevention Study showed continued cardiovascular benefit extending beyond the active treatment period, supporting the concept that longer treatment duration modifies ASCVD trajectory. 1

• Discontinuation leads to LDL-C rebound. PCSK9 inhibitors do not modify the underlying genetic or metabolic defect; stopping therapy results in return to pre-treatment LDL-C levels within weeks. 1

Monitoring Algorithm During Long-Term Therapy

Initial phase (first 3-6 months):

• Measure LDL-C at 4 weeks after initiating PCSK9 inhibitor therapy. 1, 3
• For alirocumab, assess LDL-C at week 8 to guide dose titration at week 12 (increase from 75 mg to 150 mg if LDL-C ≥70 mg/dL). 3
• Repeat lipid panel at 12 weeks to confirm target achievement. 1

Maintenance phase:

• Measure LDL-C annually once stable target is achieved. 3
• Monitor for injection-site reactions (occur in <5% of patients, typically mild). 1
• No routine laboratory monitoring for liver enzymes or creatine kinase is required. 3

Target LDL-C levels:

• Very high-risk ASCVD patients: <55 mg/dL with ≥50% reduction from baseline. 1, 3
• High-risk patients without multiple events: <70 mg/dL. 1
• Heterozygous FH without ASCVD: <100 mg/dL (or <70 mg/dL with additional risk factors). 1

Situations Warranting Dose Adjustment (Not Discontinuation)

Down-titration considerations:

• If two consecutive LDL-C values <25 mg/dL on alirocumab 150 mg, consider reducing to 75 mg. 3
• If two consecutive LDL-C values <15 mg/dL on alirocumab 75 mg, temporary discontinuation may be considered, but this occurred in only 7.7% of ODYSSEY OUTCOMES participants. 3
• Very low LDL-C levels (<25 mg/dL) are safe based on current evidence up to 4 years, with no adverse effects on steroid hormone production, bile acid metabolism, or neuronal function. 1

Critical Pitfall: Discontinuation of Concomitant Statin/Ezetimibe

A major real-world problem is inappropriate discontinuation of oral lipid-lowering therapy after PCSK9 inhibitor initiation:

• Recent Norwegian registry data (2025) show that 65% of patients stopped statins and 58% stopped ezetimibe within 12 months of starting PCSK9 inhibitors, despite guidelines mandating continuation of maximally tolerated statin plus ezetimibe. 4

• PCSK9 inhibitors are add-on therapy, not replacement therapy. The cardiovascular outcomes data (FOURIER, ODYSSEY OUTCOMES) were generated in patients receiving PCSK9 inhibitors on top of background statin ± ezetimibe therapy. 1, 3

• Patients must continue maximally tolerated statin plus ezetimibe indefinitely alongside the PCSK9 inhibitor to achieve the proven cardiovascular benefit. 1, 2

When to Consider Stopping PCSK9 Inhibitor Therapy

There are no guideline-recommended timepoints for routine discontinuation. However, stopping may be appropriate in these specific scenarios:

• Patient achieves and maintains LDL-C <25 mg/dL on two consecutive measurements and clinician judges risk of very low LDL-C outweighs benefit (though current evidence does not support safety concerns at these levels). 1, 3

• Development of intolerable injection-site reactions that persist despite switching between alirocumab and evolocumab. 1, 5

• Patient preference or adherence issues that make biweekly or monthly injections unsustainable; in this case, consider switching to inclisiran (every 6 months) rather than stopping PCSK9 inhibition entirely. 3

• Cost or access barriers that make continued therapy financially unsustainable, though this should prompt discussion of patient assistance programs rather than automatic discontinuation. 1, 3

Summary Treatment Algorithm

1. Initiate PCSK9 inhibitor in eligible patients (ASCVD or HeFH with LDL-C ≥70 mg/dL despite maximal statin + ezetimibe). 1

2. Continue indefinitely as long as patient remains above LDL-C target and tolerates therapy. 1

3. Monitor LDL-C at 4 weeks, 12 weeks, then annually. 1, 3

4. Maintain background statin plus ezetimibe at maximally tolerated doses throughout PCSK9 inhibitor therapy. 1, 2, 4

5. Adjust PCSK9 inhibitor dose (not discontinue) if LDL-C falls below 25 mg/dL on two consecutive measurements. 3

6. Reassess annually for continued indication, tolerability, and cost-effectiveness, but default to continuation unless specific contraindication develops. 1